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The literature demonstrates that hepatic steatosis reduces the tolerance of immunosuppression in 
people with inflammatory bowel disease (IBD). It also shows that elevated methylmercaptopurine 
(MMP) may-be responsible for thiopurine induced hepatitis. We sought to investigate the 
relationship between hepatic steatosis, MMP and alanine transaminase (ALT). Our hypothesis was 
that patients with hepatic steatosis would develop an ALT rise at a lower level of MMP than patients 
without steatosis. 
Methods 
To investigate this we performed a retrospective review of patients started on azathioprine 
treatment at University Hospitals Bristol NHS Foundation Trust between 2014 and 2017. There were 
600 patients in total. 121 patients met our inclusion criteria which were at least one ultrasound scan 
commenting on the appearance of the liver, liver function tests (LFTs) at commencement of 
azathioprine and LFTs and an MMP level between 6 and 8 weeks after starting treatment. 
Results 
Of 121 patients included in our study, 40 patients (33%) were identified as having radiological 
hepatic steatosis on ultrasound imaging and 81 patients had no evidence of steatosis. We found a 
positive association between MMP levels and change in alanine transaminase (ALT) in patients with 
fatty liver (P<.001) but not in those with a normal liver on ultrasound imaging. We also found that 
patients with hepatic steatosis had higher MMP levels than those without steatosis (P=.03) despite 
being on lower doses of azathioprine per kilogram of body weight.   
Conclusions 
We conclude that the higher levels of MMP are a risk factor for hepatitis in patients with hepatic 
steatosis but not in those with a normal liver, rejecting our hypothesis. In addition, patients with 
hepatic steatosis tend to produce more MMP.  
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Introduction  
Liver pathology in inflammatory bowel disease (IBD) is common and has been reported in 10-20% of 
patients with IBD [1,2]. Besides primary sclerosing cholangitis the two most frequent causes of 
deranged liver function tests in IBD are drug induced hepatotoxicity and non-alcoholic fatty liver 
disease [1].  
Drug induced hepatotoxicity in IBD is often due to thiopurines (azathioprine and 6-mercaptopurine) 
[3].  These drugs have been reported to induce liver injury in up to 17% of patients [4].  
Azathioprine is a prodrug which rapidly degrades to 6-mercaptourine (6MP) in the body via a non-
enzymic process. Three enzymes then compete to metabolise 6MP: xanthine oxidase (XO), 
thiopurine methyltransferase (TPMT) and hypoxanthine phosphoribosyltransferase (HPRT).  It is 
HRPT that is responsible for the production of the active metabolites of thiopurines, the thioguanine 
nucleotides (TGNs), which interfere with DNA synthesis and exert the therapeutic effect (Fig 1)[5]. 
TPMT, leads to the production of methylmercaptopurine (MMP) which has been implicated in the 
hepatotoxic effects of thiopurines [4].  
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing and has been reported as 
20-30% in western populations [6]. It is also being increasingly recognised in the IBD population with 
a similar prevalence of 23% being seen in this group [7,8]. Although diabetes mellitus and obesity are 
the predominant risk factors it has been suggested that corticosteroid use and IBD are also 
independently associated with developing NAFLD [7,9].  
NAFLD has been shown to significantly alter the metabolism of many drugs which may lead to 
altered pharmacokinetics and increased risk of adverse drug reactions [10]. It has previously been 
reported that hepatic steatosis is a risk factor for developing hepatotoxicity in patients with IBD on 
immunosuppression [11]. With treatment options for IBD limited, understanding the mechanisms 
behind drug intolerance is of significant importance in guiding optimal medical treatment.  
This study looks at the development of azathioprine induced hepatotoxicity in IBD patients with 
hepatic steatosis, and the role of MMP level.   
 
Figure 1  


















We performed a retrospective review of the medical records of patients started on azathioprine for 
IBD at University Hospitals Bristol NHS Foundation Trust between June 2014 and May 2017. The 
medical records of patients identified were analysed on the basis of meeting the inclusion criteria of:  
(i) at least one abdominal ultrasound commenting on the appearance of the liver, (ii) liver function 
tests at the commencement of treatment with azathioprine and (iii) liver function tests and an MMP 
level at 6-8 weeks after starting treatment.  
An abdominal ultrasound scan carried out within 5 years of commencing treatment was used to 
identify hepatic steatosis. Ultrasound reports commenting on the appearance of the liver were 
considered and results categorised as either showing radiological evidence of steatosis or no 
steatosis. Patients with evidence of liver cirrhosis, other liver pathologies or ultrasound reports not 
clearly commenting on the liver were excluded (Fig 2).  
Liver function tests were measured at commencement of azathioprine and at 6-8 weeks after 
starting treatment. A change in the level of alanine transaminase (ALT) over this 6 week period was 
calculated and used as a marker of hepatotoxicity. MMP and TGN levels were also measured at 
between 6 and 8 weeks.  
The primary outcome measure was the change in ALT level from commencement of azathioprine in 
the ‘steatosis’ versus ‘no steatosis’ groups and how that related to MMP level. The secondary 
outcome measure was whether or not MMP levels were different in the ‘steatosis’ vs ‘non steatosis’ 
groups. 
Variables recorded included sex, age and weight, disease entity and presence of diabetes mellitus as 
a comorbidity.  
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A total of 121 patients with IBD were suitable for inclusion in the study. Of these 60 (49.6%) were 
male and 61 (50.4%) were female with a median age of 36 years (interquartile range, IQR, 23-49, 
range of 9-77 years). All patients were on treatment with azathioprine. Of the 121 patients included 
88 (72.7%) had Crohn’s disease, 22 (18.2%) had ulcerative colitis and 11 (9.1%) had indeterminate 
colitis and. The mean weight of included patients was 73.3kg (standard deviation, SD, 20.6kg, range 
24.8-157.2kg) and 3 patients (2.5%) had diabetes mellitus as a comorbidity. Body mass index (BMI) 
was only available for 97 of 121 included patients. The mean dosing of azathioprine was 1.88mg/kg 
(1.95mg/kg in the no steatosis group and 1.75mg/kg in the steatosis group).  
All included patients had an abdominal ultrasound scan within 5 years of commencing azathioprine. 
Ultrasound reports revealed radiological evidence of hepatic steatosis in 39 patients (32.2%).  
The primary outcome measures were change in ALT and MMP level. Change in ALT was measured 
from commencement of azathioprine to 6 - 8 weeks after starting treatment, the mean change in 
ALT in patients with hepatic steatosis was 8.2U/L (SD 13.9). The median MMP level at 6 - 8 weeks 
after commencing azathioprine was 1151 pmol /8x108 cells (IQR 471-3109 pmol /8x108 cells). This 
data is shown in Table 1.  
To determine the interaction between hepatic steatosis, hepatotoxicity and MMP level, we 
compared the change in ALT with the MMP level at 6 weeks in the steatosis vs no steatosis groups. 
Both subgroups were comparable with respect to gender and disease entity. However, the mean 
weight of patients in the steatosis group was 89.3.0kg (SD 20.1kg) compared with 65.8kg (SD 16.0kg) 
in the no steatosis group. Also, the 3 patients with diabetes mellitus were all within the hepatic 
steatosis subgroup.  
Using a Wilcoxon rank-sum test, our results found weak evidence of higher MMP levels at 6 weeks in 
patients with hepatic steatosis compared to those  without steatosis (median MMP = 1859 pmol 
/8x108 cells vs 967 pmol /8x108 cells for those with and without steatosis respectively, P= .04). The 
median TGN level was 294 6-TGN/8x10 (IQR 167-424). The median TGN level in the hepatic steatosis 
group was 315 6-TGN/8x10 (IQR 174-509 6-TGN/8x10) compared to 294 6-TGN/8x10 (IQR 167-3946-
TGN/8x10) in patients with no evidence of steatosis on ultrasound (P=0.40).  
Linear regression found strong evidence of an interaction between the presence of hepatic steatosis 
and MMP levels. ALT levels for patients with hepatic steatosis increased by 0.26 U/L per 100 
pmol/8x108 increase in MMP compared with patients without hepatic steatosis (95% CI 0.10 to 0.41, 
P=0.002).   
Graph 1 displays the change in ALT with increasing MMP level in patients with an ultrasound 
consistent with fatty liver disease versus those with a radiologically normal liver on ultrasound. The 
respective lines of best fit show the positive correlation between rising MMP levels and change in 




Table 1  
Overview of all patients (n=121)  
Demographic data   
Age (years)* 36 (23-49) 
Male [n (%)] 60 (49.6) 
Azathioprine dose ( mg/kg)^ 1.88 
Metabolic profile  
Weight (kg)^ 73.3 (20.6) 
BMI (kg/m2)^ 26.6 (6.7) 
Diabetes mellitus [n (%)] 3 (2.5%) 
Disease entity [n (%)]  
Crohn’s disease 88 (72.7%) 
Indeterminate colitis 11 (9.1%) 
Ulcerative colitis 22 (18.2%) 
Primary outcomes  
Steatosis [n (%)] 39 (32.2%) 
Change ALT (U/L)^ 2.1 (11.1) 
MMP level (pmol /8x108 cells)* 1151 (471-3109) 
TGN level (6TGN/8x10)* 294 (167-424) 
*median (25%-75%)  







Table 2  
Hepatic Steatosis   
 No steatosis Hepatic steatosis P-value 
Total [n (%)] 82 (67.8) 39 (32.2)  
Demographic data    
Age (years) 31 (22-42) 47 (31-56)  <0.001* 
Male [n (%)] 42 (51%) 19 (49%)  
Female [n (%)] 40 (48%) 20 (52%)   
Gender   0.90** 
Azathioprine dose          
(mg/kg)^ 
1.95 1.73  
Metabolic profile    
Weight (kg)^ 65.8 (16.0) 89.3 (20.1) <0.001+ 
BMI (kg/m2)^ 23.6 (3.9) 31.9 (7.3) <0.001+ 
Diabetes mellitus [n (%)] 0 (0) 3 (8%) 0.01** 
Disease entity [n (%)]    
Crohn’s disease 58 (71%) 30 (77%)  
Indeterminate colitis 7 (9%) 4 (10%)   
Ulcerative colitis 17 (21%) 5 (13%)   
Primary outcomes    
Change ALT (U/L)^ -1.20 (7.50) 8.19 (13.9) <0.001+ 
MMP level (pmol /8x108 
cells)* 
967 (393-2857) 1859 (762-4500) 0.04* 
TGN level (6TGN/8x10)*  294 (167-397) 315 (174-509) 0.40* 
*median (25%-75%)  
^mean (standard deviation) 
*P value from Wilcoxon’s rank sum test  , **P values from Chi-square test, +P values from t-test   
Graph 1  
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Discussion  
The literature suggests that people with inflammatory bowel disease (IBD) and hepatic steatosis do 
not tolerate the immunosuppression used in IBD [10].  However, previous studies have not 
measured MMP levels. Our initial hypothesis was that people with hepatic steatosis may suffer an 
elevation in ALT at a lower level of MMP than people without steatosis.  
We performed a retrospective review of IBD patients started on azathioprine treatment at the 
University Hospitals Bristol NHS Foundation Trust between 2014 and 2017. There were 600 patients 
in total. We included 121 patients who met the following criteria: i) at least one abdominal USS with 
specific reference to the appearance of the liver and ii) LFTs taken at the time of commencing 
azathioprine and then LFTs  and MMP between 6 and 8 weeks post commencement.  
The main findings of our study were that there is a positive association between MMP levels and a 
change in alanine transaminase (ALT) in patient with fatty liver on ultrasound (P<.001) but not in 
patients with a radiologically normal liver, refuting our initial hypothesis. Also, it appears that 
patients with hepatic steatosis had higher MMP levels than patients without steatosis (P=.04). 
Together, this suggests that a fatty liver is less tolerant of an elevated MMP and tends to produce 
more MMP.  
The prevalence of non-alcoholic fatty liver disease (NAFLD) is rising and has been reported as 20-30% 
in western populations [6]. It is also being increasingly recognised in the IBD population with a 
similar prevalence in this group [7,8]. The gold standard for diagnosis of NAFLD is liver biopsy [12]; 
we therefore accept that using ultrasound to look for evidence of fatty infiltration of the liver is a 
limitation of our study. However, ultrasound has been shown to be a useful tool for the detection of 
liver steatosis, allowing reliable and accurate results. The positive likelihood ratio and negative 
likelihood ratio of ultrasound for the detection of moderate-severe fatty liver, compared to 
histology, were 13.3 and 0.16 respectively [13,14]. 
 
We included ultrasound imaging within 5 years of commencing azathioprine to detect hepatic 
steatosis. It is therefore possible that azathioprine caused hepatic steatosis and an ALT rise in 
susceptible individuals. A prospective study would be required to assess this further.  
With regard to our data, we found a prevalence of fatty liver of 32.2%, which is on the higher than 
expected range. However, this may be accounted for by our selection of patients who have required 
investigation of the liver with hepatic ultrasound. Three patients in the hepatic steatosis group had 
diabetes mellitus, compared to none in the group with a normal liver (P=.01). Mean BMI in the 
steatosis group was 31.9kg/m2 compared with 23.6kg/m2 in the no steatosis group (P<.001). The 
mean age was 47 years for those with steatosis compared to 31 years for those without (P<.001). 
Diabetes mellitus, obesity and advancing age are known risk factors for NAFLD consistent with those 
patients having pre-existing fatty liver disease [15].  
Patients were excluded if there was evidence of any other liver pathology on USS or those with 
evidence of pre-existing hepatitis on blood tests. In our case no patients were excluded at this point. 
This was done with the intention of showing that hepatotoxicity was directly related to 
immunosuppression and not related to any other cause.  It is not possible to say for certain that the 
hepatitis is the direct result of immunosuppression without a detailed history of alcohol and other 
substances causing hepatotoxicity, performing a full non-invasive liver screen to look for other 
infective, inflammatory or autoimmune conditions and performing a liver biopsy. However, in the 
absence of any diagnosed, underlying liver pathology we suspect any identified hepatotoxicity is a 
direct result of azathioprine.  
It is important to note that the incidence of hepatotoxicity in relation to IBD immunosuppressive 
therapies varies depending upon the definition of hepatotoxicity, but is reported as being between 0 
and 17% [3,4,16]. In this study we looked specifically at ALT as a marker of possible hepatotoxicity 
and used any elevation in ALT to indicate hepatotoxicity.  The average rise in ALT in patients with 
radiological hepatic steatosis was 8.19U/L. We accept that this does not necessarily represent a 
clinically significant rise. However, in patients with no ultrasound evidence of liver steatosis the 
average change in ALT was –1.20U/L and the P value for the difference between the two groups was 
<.001 which is therefore a statistically significant numeric difference between the groups.  
The clinical relevance of elevations in liver enzymes in IBD is a matter of debate. However, as even 
mild elevations in ALT may be associated with liver injury and mortality from liver disease, close 
monitoring of liver biochemistry in patients being treated with azathioprine is recommended 
[17,18,19,20].  
It has previously been reported that MMP is associated with hepatotoxicity at levels above 
5700pmol /8x108 cells [4]. In our study there were a range of MMP levels across the 2 groups with 4 
patients from each group having an MMP level of >5700 at 6 weeks. The median MMP levels 
recorded were 1859 pmol /8x108 cells in the liver steatosis group and 967 pmol /8x108 cells in the 
radiologically normal liver group (P=.04). This may suggest that patients with hepatic steatosis 
metabolise azathioprine differently, resulting in higher levels of MMP. The median TGN level for 
both groups was within the therapeutic range with a P value=0.40 suggesting no statistically 
significant difference between the two groups.  
Average dosing of azathioprine across both groups was 1.88mg/kg which is slightly lower than the 
recommended therapeutic dose of 2.5mg/kg. The mean in patients with radiological steatosis was 
1.73mg/kg compared to 1.95mg/kg in the group with a radiologically normal liver. This suggests that 
the higher metabolite levels were not due to higher dosing, but to differences in metabolism.  
The linear regression analysis found strong evidence of an interaction between presence of hepatic 
steatosis, MMP levels and change in ALT (P<.001).  
It may be that non-alcoholic fatty liver disease is a first hit for promoting liver injury in IBD patients, 
making them more susceptible to a high level of MMP (a second hit). Our data suggests that the 
hepatotoxic effects of high levels of MMP may only be relevant in those patients with hepatic 
steatosis. However, as a single centre study, only four patients in each group had MMP levels 
>5700pmol/8x108, a concordant study containing more patients with high MMP would be needed to 
confirm this finding.  
Our study is consistent with previously published research suggesting that non-alcoholic fatty liver 
disease is a risk factor for the development of hepatotoxicity in IBD patients on thiopurines. We have 
gone further to implicate MMP in this process concluding that patients with hepatic steatosis may be 
more sensitive to MMP and may metabolise azathioprine differently. As the options for the 
management of IBD remain finite and the prevalence of NAFLD continues to rise, improving our 
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